33P: A multi-country time & motion (T&M) study of subcutaneous (SC) vs intravenous (IV) pembrolizumab (Pembro) plus chemotherapy (Chemo) in metastatic non-small cell lung cancer (mNSCLC)
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A time and motion study suggested that subcutaneous pembrolizumab can improve administration workflow by reducing active time for providers and chair time for patients.
“A time and motion study suggested that pembrolizumab s.c.can improve administration workflow by reducing active time for providers and chair time for patients.24”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Felip, E., Rojas, C. I., Schenker, M., Kowalski, D. M., Casarini, I. A., Csöszi, T., Şendur, M. A. N., Martins, J., Calles Blanco, A., Wang, C.-C., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.012 · Cited by 40 · see citing works
Self-citation
- Authors
- De Cock, E., Oskar, S., Lourdudoss, C., Eiras, R., Pietanza, C., Arunachalam, A., Alves, G. V., & Felip, E.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Vall d'Hebron Hospital Universitari (ES)
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2025-03
- Volume
- 20
- Issue
- 3
- Pages
- S32
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W4408979072
- Cited by
- 1
- References
- 0
- Citations by year
- 2025: 1
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- pembrolizumab, subcutaneous administration, intravenous infusion, metastatic non-small cell lung cancer, time and motion study, chemotherapy, infusion duration, non-inferiority
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
